Relevant bibliographies by topics / Warfarin

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Warfarin'

Author: Grafiati
Published: 4 June 2021
Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Warfarin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Warfarin"

1

Alsancak, Yakup, Serkan Sivri, Telat Keleş, Tahir Durmaz, and Engin Bozkurt. "A rare complication of warfarin: late onset warfarin induced skin necrosis." Türk Aile Hekimliği Dergisi 21, no. 1 (2017): 41–43. http://dx.doi.org/10.15511/tahd.17.00141.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Li, Qiang, Wen-yue Yang, Ling-ling Qu, Huan-Yang Qi, Yun Huang, and Zheng Zhang. "Interaction of Warfarin with Human Serum Albumin and Effect of Ferulic Acid on the Binding." Journal of Spectroscopy 2014 (2014): 1–7. http://dx.doi.org/10.1155/2014/834501.

Full text
Abstract:
Angelica sinensis(Oliv.) Diels combined treatment with warfarin would increase the risk of bleeding. Ferulic acid is an abundant hydroxycinnamic acid inA. sinensisand warfarin is the most widely used oral anticoagulant. The studies on supermolecular interaction of warfarin with human serum albumin (HSA) and the influence of ferulic acid on the binding would contribute to the understanding of the metabolic processes of warfarin and the effect of ferulic acid. We focus on investigating the effect of warfarin on fluorescence spectrum of human serum albumin (HSA), fluorescence quenching mechanism,
APA, Harvard, Vancouver, ISO, and other styles
3

Thompson, Dennis F., Marsha A. Raebel, Elizabeth K. Hussey, and George E. Dukes. "Do All Histamine2-Antagonists Cause a Warfarin Drug Interaction?" DICP 23, no. 9 (1989): 675–79. http://dx.doi.org/10.1177/106002808902300911.

Full text
Abstract:
Cimetidine, the first marketed histamine2-receptor antagonist, has been shown to decrease the clearance of warfarin consistently through inhibition of cytochrome P-450 metabolism. The clinical significance of this drug–drug interaction has been questioned due to: (1) the lowering of the warfarin therapeutic range, (2) the lowering of the total daily therapeutic cimetidine dosage, (3) the advent of once-daily cimetidine dosing, and (4) the demonstration that the clearance of the less active warfarin R-enantiomer is decreased to a greater extent than the more active S-enantiomer. Ranitidine has
APA, Harvard, Vancouver, ISO, and other styles
4

Jaffer, Amir, Jason Hurbanek, Nariman Morra, and Daniel Brotman. "Warfarin prophylaxis and venous thromboembolism in the first 5 days following hip and knee arthroplasty." Thrombosis and Haemostasis 92, no. 11 (2004): 1012–17. http://dx.doi.org/10.1160/th04-04-0204.

Full text
Abstract:
SummaryMany orthopaedic surgeons use warfarin to prevent venous thromboembolism (VTE) following hip or knee arthroplasty. Since warfarin’s antithrombotic effects are delayed, we hypothesized that early VTE (occurring within 5 days post-operatively) would be more common in arthroplasty patients receiving warfarin monotherapy compared to those receiving enoxaparin. We performed a secondary analysis of a case-control study examining risk factors for post-operative thrombosis in postmenopausal women. We defined cases as patients who were diagnosed with thrombosis within 5 days of surgery. Controls
APA, Harvard, Vancouver, ISO, and other styles
5

Meeks, Mimi L., Kenneth W. Mahaffey, and Michael D. Katz. "Danazol Increases the Anticoagulant Effect of Warfarin." Annals of Pharmacotherapy 26, no. 5 (1992): 641–42. http://dx.doi.org/10.1177/106002809202600506.

Full text
Abstract:
OBJECTIVE: To report two cases demonstrating an interaction between danazol and warfarin, resulting in the potentiation of warfarin's effect and bleeding complications. DATA SOURCES: Case reports, review articles, and studies identified by MEDLINE. STUDY SELECTION: All published English-language reports involving danazol and warfarin interactions were reviewed. DATA SYNTHESIS: Danazol, a synthetic testosterone derivative, is used in the treatment of endometriosis, fibrocystic breast disease, menorrhagia protein C deficiency, and hemophilia. We describe two cases including an interaction betwee
APA, Harvard, Vancouver, ISO, and other styles
6

Milligan, Paul E., Gerald A. Banet, Amy D. Waterman, Susan K. Gatchel, and Brian F. Gage. "Substitution of Generic Warfarin for Coumadin in an HMO Setting." Annals of Pharmacotherapy 36, no. 5 (2002): 764–68. http://dx.doi.org/10.1345/aph.1a327.

Full text
Abstract:
BACKGROUND: Substitution of generic warfarin for Coumadin presents safety concerns due to warfarin's narrow therapeutic index and because a prior generic formulation was removed from the US market after it was associated with adverse events. OBJECTIVE: To determine whether a health maintenance organization (HMO) can add generic warfarin to its formulary without adversely affecting warfarin management or increasing adverse events. DESIGN: In a prospective, observational study, an HMO that formerly dispensed only Coumadin added a generic warfarin preparation (Barr Laboratories, Pomona, NY) to it
APA, Harvard, Vancouver, ISO, and other styles
7

Jones, Cade B., and Susan E. Fugate. "Levofloxacin and Warfarin Interaction." Annals of Pharmacotherapy 36, no. 10 (2002): 1554–57. http://dx.doi.org/10.1345/aph.1c074.

Full text
Abstract:
OBJECTIVE: To report 4 cases of hypoprothrombotic response resulting from addition of levofloxacin therapy to chronic warfarin therapy and to review related literature to support or refute a warfarin—levofloxacin interaction. CASE SUMMARY: Four patients, 34–81 years old, were prescribed levofloxacin concomitantly with stable warfarin therapy. Three patients had a target international normalized ratio (INR) range of 2.0–3.0 and experienced an increase in INR to 3.5, 8.12, and 11.5 on days 11, 5, and 4 of a 10-day course of levofloxacin, respectively. The fourth patient experienced minor bleedin
APA, Harvard, Vancouver, ISO, and other styles
8

Umashankar, Niroja, and Binju Mercy Oommen. "The role of warfarin in anticoagulation therapy: Current insight’s and clinical perspectives." Indian Journal of Pharmacy and Pharmacology 11, no. 4 (2024): 178–84. https://doi.org/10.18231/j.ijpp.2024.031.

Full text
Abstract:
Warfarin, a widely used oral anticoagulant and vitamin K antagonist, plays a critical role in the prevention and treatment of venous thrombosis and thromboembolic complications. This review explores the pharmacological properties, pharmacokinetics, pharmacodynamics, therapeutic monitoring, and drug-food interactions of warfarin. By inhibiting vitamin K-dependent clotting factors, warfarin induces a controlled anticoagulation state. However, its narrow therapeutic index presents challenges in achieving and maintaining optimal dosing. Regular monitoring of the International Normalized Ratio (INR
APA, Harvard, Vancouver, ISO, and other styles
9

Casserly, Elizabeth A., Sara E. Rogers, and Sidney V. Keisner. "Lack of interaction between enzalutamide and warfarin in a metastatic castration-resistant prostate cancer patient." Journal of Oncology Pharmacy Practice 23, no. 1 (2016): 68–70. http://dx.doi.org/10.1177/1078155215609979.

Full text
Abstract:
Enzalutamide is an androgen receptor antagonist used for the treatment of metastatic castration-resistant prostate cancer. Enzalutamide is classified as a strong cytochrome P450 3A4 inducer, a moderate 2C9 and 2C19 inducer, and a time-dependent inducer of 1A2. Warfarin’s more potent enantiomer is primarily metabolized by cytochrome P450 2C9 and has a narrow therapeutic window. Enzalutamide is thought to decrease therapeutic warfarin concentrations per pharmacokinetic studies performed during drug development. This case report describes a 59–year-old man undergoing treatment with enzalutamide f
APA, Harvard, Vancouver, ISO, and other styles
10

Kim, Karissa Y., and Michael A. Mancano. "Fenofibrate Potentiates Warfarin Effects." Annals of Pharmacotherapy 37, no. 2 (2003): 212–15. http://dx.doi.org/10.1177/106002800303700210.

Full text
Abstract:
OBJECTIVE: To describe 2 patients in whom the initiation of fenofibrate potentiated warfarin's anticoagulant effects. CASE SUMMARY: A 71-year-old white woman and an 80-year-old white woman with multiple medical conditions were both stabilized on long-term warfarin therapy. During the course of anticoagulation, both patients were prescribed fenofibrate and experienced threefold and twofold increases in international normalized ratio (INR), respectively, requiring total weekly warfarin dosage reductions of 30–40%. Before starting fenofibrate therapy, both patients' coagulation values were within
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Warfarin"

1

Zhang, Jieying Eunice. "Pharmacogenetics of warfarin." Thesis, University of Liverpool, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.569544.

Full text
Abstract:
Warfarin is one of the most commonly used oral anticoagulants worldwide and is highly efficacious for the treatment and prevention of thromboembolic disorders. However, due to its narrow therapeutic index and large interindividual variability, it remains a challenging drug to prescribe. Genetic factors (CYP2C9 and VKORCI), together with clinical factors (age and body weight), account for up to 60% of warfarin dose variance but the remaining ~40% variability remains unexplained. A polymorphism rs2108622 in CYP4F2, a vitamin K oxidase, has previously been associated with increased warfarin stabl
APA, Harvard, Vancouver, ISO, and other styles
2

Ab, Ghani Azizah. "Pharmacogenetics in warfarin therapy." Thesis, University of Liverpool, 2013. http://livrepository.liverpool.ac.uk/18317/.

Full text
Abstract:
Warfarin is a challenging drug to dose accurately, especially during the initiation phase because of its narrow therapeutic range and large inter-individual variability. Therefore, the aim of this thesis was to investigate the use of pharmacogenetics and clinical data to improve warfarin therapy. Genetic variants in cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) are known to influence warfarin dose. Therefore we developed a pharmacogenetic dosing algorithm to predict warfarin stable dose prospectively in a British population based on 456 patients who started warfarin in
APA, Harvard, Vancouver, ISO, and other styles
3

Choiniere, Jennifer. "Content and Uniformity of Mexican Manufactured Lovastatin and Warfarin Versus American Manufactured Lovastatin and Warfarin." The University of Arizona, 2005. http://hdl.handle.net/10150/624720.

Full text
Abstract:
Class of 2005 Abstract<br>Objective: To analyze the quantity of active ingredient as well as the content uniformity of lovastatin and warfarin manufactured in Mexico as compared to the lovastatin and warfarin manufactured in the United States. Methods: High-pressure liquid chromatography assays modified from the U.S. Pharmacopoeia will be used to evaluate the amount of active ingredient found in lovastatin and warfarin manufactured in Mexico and America. Area-under-the-curve analysis was done to evaluate relative quantities of the active ingredients. Results: The amount of lovastatin found i
APA, Harvard, Vancouver, ISO, and other styles
4

Ghaswalla, Parinaz K. "Medication-Related Problems in Older Adults: A Focus on Underuse of Warfarin and Warfarin-Antibiotic Interactions." VCU Scholars Compass, 2011. http://scholarscompass.vcu.edu/etd/2631.

Full text
Abstract:
The work presented in this dissertation focuses on two important medication-related problems in older adults, that is, untreated indication and drug-drug interactions, specifically with respect to a high-risk medication such as warfarin. Warfarin is a challenge to use in clinical practice due to its narrow therapeutic index, variability in dose-response and its interactions with numerous foods and drugs. This dissertation presents the research from two projects. In the first project the prevalence and predictors of warfarin use in nursing home (NH) residents with atrial fibrillation (AF), and
APA, Harvard, Vancouver, ISO, and other styles
5

Eriksson, Niclas. "On the Prediction of Warfarin Dose." Doctoral thesis, Uppsala universitet, Klinisk farmakologi, 2012. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-172864.

Full text
Abstract:
Warfarin is one of the most widely used anticoagulants in the world. Treatment is complicated by a large inter-individual variation in the dose needed to reach adequate levels of anticoagulation i.e. INR 2.0 – 3.0. The objective of this thesis was to evaluate which factors, mainly genetic but also non-genetic, that affect the response to warfarin in terms of required maintenance dose, efficacy and safety with special focus on warfarin dose prediction. Through candidate gene and genome-wide studies, we have shown that the genes CYP2C9 and VKORC1 are the major determinants of warfarin maintenanc
APA, Harvard, Vancouver, ISO, and other styles
6

Chen, Y. Y. "Genetics of the anticoagulant drug warfarin." Thesis, University of Cambridge, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.597528.

Full text
Abstract:
In this thesis I use the most widely prescribed anticoagulant drug, warfarin, as a model to investigate the effect of genetic determinants on drug efficacy and safety. Following a literature review of all the genes involved in warfarin pharmacokinetics and pharmacodynamics, 35 candidate genes were selected for investigation. Two independent Swedish cohorts of warfarin-treated patients were analysed. First linkage disequilibrium maps were constructed for each gene. Selected SNPs integrated with putative functional variants were genotyped in 201 patients recruited at the Uppsala University. A pa
APA, Harvard, Vancouver, ISO, and other styles
7

Khan, Tayyaba Irfan. "Factors affecting anticoagulation response to Warfarin." Thesis, University of Newcastle Upon Tyne, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.413389.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Myszka, David Gerard. "Photoaffinity labeling of warfarin binding proteins /." The Ohio State University, 1991. http://rave.ohiolink.edu/etdc/view?acc_num=osu1487694702785693.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Msolli, Ines. "Nanosystèmes polymères pour la libération contrôlé de la Warfarine : conception et évaluation biologique." Thesis, Sorbonne Paris Cité, 2016. http://www.theses.fr/2016USPCD033/document.

Full text
Abstract:
Dans ce travail de thèse, nous avons synthétisé des dérivés de poly(acide (R,S)-3,3-diméthylmalique) (PDMMLA). Les copolymères de PDMMLA sont composésprincipalement de deux monomères: un monomère hydrophobe contenant un groupementhexylique et un monomère hydrophile contenant un groupement acide. Grâce à la proportionde chaque monomère dans le copolymère final, la balance hydrophile/hydrophobe est ajustée.Donc six copolymères ont été obtenus: trois copolymères statistiques PDMMLAHn-co-Hex100-n et trois copolymères à blocs PDMMLAHn-b-Hex100-n. Ces copolymères sont àl’origine de nanoparticules sa
APA, Harvard, Vancouver, ISO, and other styles
10

Hickmott, Helen Ruth. "Factors affecting the pharmacological activity of warfarin." Thesis, University of Newcastle Upon Tyne, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.251170.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Warfarin"

1

Royal College of General Practitioners. and National Patient Safety Agency, eds. Special focus: Warfarin. Royal College of General Practitioners, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wessler, Stanford, Carl G. Becker, and Yale Nemerson, eds. The New Dimensions of Warfarin Prophylaxis. Springer US, 1987. http://dx.doi.org/10.1007/978-1-4757-5985-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

1917-, Wessler Stanford, Becker Carl G, and Nemerson Yale, eds. The new dimensions of warfarin prophylaxis. Plenum Press, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lodwick, Al. Warfarin, rat poison to wonder drug: A guide to its use and interactions. Lodwick Pub., 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bowles, Jane Anne. A comparison of different methods of prescribing warfarin. St. Joseph's Hospital, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Parker, James N., and Philip M. Parker. Warfarin: A medical dictionary, bibliography, and annotated research guide to Internet references. Edited by NetLibrary Inc. ICON Health, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Reuter, Gisela. Stopped-flow spektrometrische Untersuchungen zum Einfluss der Ölsäure auf die Bindung von Warfarin an Humanserumalbumin. [s.n.], 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Sullivan, Daniel. Acceptance of various rodenticide baits under field conditions by Columbian and Richardson ground squirrels. Montana Dept. of Agriculture, Environmental Management Division, Technical Services Bureau, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Parker, Philip M., and James N. Parker. Coumadin: A medical dictionary, bibliography, and annotated research guide to internet references. ICON Health Publications, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kwan, Debora. The effects of acute and chronic acetaminophen dosing on the pharmacodynamics and pharmacokinetics of the (R)- and (S)- enantiomers of warfarin. National Library of Canada, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Warfarin"

1

Herridge, Margaret S., Jane Batt, and Scott K. Epstein. "Warfarin." In Encyclopedia of Intensive Care Medicine. Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-00418-6_2432.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hadlock, Gregory C., Allison E. Burnett, and Edith A. Nutescu. "Warfarin." In Anticoagulation Therapy. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-73709-6_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

DeLoughery, Thomas G. "Warfarin." In Hemostasis and Thrombosis. Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-09312-3_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

DeLoughery, Thomas G. "Warfarin." In Hemostasis and Thrombosis. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-19330-0_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Roth, Elliot J. "Warfarin (Coumadin)." In Encyclopedia of Clinical Neuropsychology. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-57111-9_2214.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Roth, Elliot J. "Warfarin (Coumadin)." In Encyclopedia of Clinical Neuropsychology. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-56782-2_2214-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hashim, Jeffrey, Daniel Thomas Ginat, and Juan E. Small. "Warfarin (Coumadin)." In Neuroimaging Pharmacopoeia. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-12715-6_32.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hashim, Jeffrey, Daniel Thomas Ginat, and Juan E. Small. "Warfarin (Coumadin)." In Neuroimaging Pharmacopoeia. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-08774-5_43.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Akunjee, Nazmul, Muhammed Akunjee, Dominic Pimenta, et al. "Warfarin Therapy." In The Easy Guide to OSCEs for Final Year Medical Students, Second Edition. CRC Press, 2024. https://doi.org/10.1201/9780138736835-88.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Hall, Christine M., Amaka C. Offiah, Francesca Forzano, Mario Lituania, Gen Nishimura, and Valérie Cormier-Daire. "Warfarin Embryopathy." In Fetal and Perinatal Skeletal Dysplasias, 2nd ed. CRC Press, 2024. http://dx.doi.org/10.1201/9781003166948-79.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Warfarin"

1

Huang, Yong, Charles A. Downs, and Amir M. Rahmani. "Optimizing Warfarin Dosing Using Contextual Bandit: An Offline Policy Learning and Evaluation Method." In 2024 46th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). IEEE, 2024. https://doi.org/10.1109/embc53108.2024.10782277.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Parwati, Farida Arum, Kemas Wiharja, and Isman Kurniawan. "Application of Graph Neural Network to Predict Drug-Drug Interactions on Warfarin based on Molecular Properties and Molecular Mechanism." In 2024 International Conference on Data Science and Its Applications (ICoDSA). IEEE, 2024. http://dx.doi.org/10.1109/icodsa62899.2024.10652104.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Soni, A., A. Muthyala, S. Sasidharan, R. Shrestha, J. Scott, and R. A. Rosiello. "To Warfarin or Not to Warfarin, That Is the Question!" In American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a1829.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Powers, P. J., M. Gent, R. Jay, J. Hirsh, M. Levine, and G. Turpie. "DEEP VEIN THROMBOSIS PROPHYLAXIS IN SURGICALLY TREATED FRACTURED HIP PATIENTS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643692.

Full text
Abstract:
Deep vein thrombosis is a major complication in'patients treated surgically for fractured hip. Methods employed toreduce the risk of thrombosis include dextran, ASA, warfarin, low or adjusted dose heparin and calf compression, but none has widespread acceptance.A randomized trial wascarried out to assess the effectiveness of sodium warfarinand acetyl salicylic acid(aspirin) compared to placebo inthe prevention of venous thrombosis in fractured hip patients. One hundred and ninty four patients were randomizedto receive warfarin (65 patients), ASA (66 patients) or placebo (63 patients).Prophylax
APA, Harvard, Vancouver, ISO, and other styles
5

McKernan, A., J. M. Thomson, and L. Poller. "A PROSPECTIVE RANDOMISED CONTROLLED STUDY OF MINI-DOSE WARFARIN PROPHYLAXIS OF DEEP VEIN THROMBOSIS IN MAJOR SURGERY." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643879.

Full text
Abstract:
A prospective randomised study has been undertaken to assess the clinical effectiveness of oral anticoagulation using minidose warfarin (1 mg daily for 2-4 weeks before major gynaecological surgery) compared with conventional oral anticoagulant prophylaxis and an untreated randomised control group. The conventional oral anticoagulant prophylaxis was based on a therapeutic range of 1.5 - 2.0 INR at the time of operation and 2.0 - 3.0 INR post-operatively. Overall the mini-dose warfarin group showed no pre-operative prolongation of the prothrombin time with the Manchester Reagent although a mino
APA, Harvard, Vancouver, ISO, and other styles
6

Gerhart, T., H. Yett, A. Donovan, M. A. Lee, M. Smith, and E. W. Salzman. "ORGANON 10172 VS. WARFARINTO PREVENT VENOUS THROMBOSIS AFTER HIP FRACTURE." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643686.

Full text
Abstract:
Deep venous thrombosis (DVT) remains a serious and frequent complication after fracture of the hip, and even the mostefficacious prophylactic agents, e.g., warfarin, may fail to prevent DVT in up to 2056 of cases. There is evidence that low molecular weight heparin or heparin-like agents may have advantages in antithrombotic prophylaxis with reduced hemorrhagic sideeffects in patients at risk of DVT. We are engaged in a randomized prospective trial comparing the antithrombotic effect ofwarfarin (PT 1.5x control)with that of Organon 10172, a mixture ofsulfated low molecular weight glycosamiogly
APA, Harvard, Vancouver, ISO, and other styles
7

Chi, Chih-Lin, Xinpeng Shen, Kourosh Ravvaz, John Weissert, and Peter Tonellato. "Personalize Warfarin Trearment by Optimizing Protocol Assignment." In 2018 IEEE International Conference on Healthcare Informatics (ICHI). IEEE, 2018. http://dx.doi.org/10.1109/ichi.2018.00067.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zhao, Zhongming, Shivi Kansal, and Bonny L. Bukaveckas. "SmartWarf - A portable automated warfarin dosing tool." In 2009 International Symposium on Collaborative Technologies and Systems. IEEE, 2009. http://dx.doi.org/10.1109/cts.2009.5067500.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

van den Heuvel, Robert. "Edoxaban versus warfarin in chronic thromboembolic pulmonary hypertension." In AHA Scientific Sessions 2023, edited by Marc Bonaca. Medicom Medical Publishers, 2024. http://dx.doi.org/10.55788/c719228c.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Aydar, S., S. Alataş, L. Numanoğlu, and A. Sönmezdağ. "EFFECT OF ORAL ANTICOAGULANTS ON STABLE ROSETTE FORMATION." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643271.

Full text
Abstract:
Human peripheral blood T lymphacytes when cultered in the presence of mitogen Phytohemogglutinin (PHA) acquire the capacity to form E rosettes with sheep erythrocytes that are resistant to incubation at 37° C. Whereas human thymus lymphocytes form 37° C stable E rosettes. On the other hand, it is shown that the use of anticoagulants can prevent cancer metastases which brings forth the importance of explaining the relationship between the lymphocyte functions and anticoagulant action mecha-nismus. In order to investigate this relationship, we did a group af experiments with lymphocytes of norma
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Warfarin"

1

Purba, Abdul, Saraswati Gumilang, Dhihintia Jiwangga, Nurina Hasanatuludhhiyah, and Maarten Postma. Cost and clinical outcomes in the use of new oral anticoagulants versus warfarin in deep vein thrombosis: A systematic review protocol. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.12.0106.

Full text
Abstract:
Review question / Objective: What are the benefits of using new oral anticoagulants compared to warfarin in terms of efficacy, bleeding, and cost among people with deep vein thrombosis? This study aimed to compare the effectiveness, bleeding incidence, and cost between NOAC and warfarin in DVT patients. Condition being studied: The patient confirmed DVT with the results of the Wells' score and D-dimer test stating "possible DVT" and followed by an ultrasound examination which stated "DVT positive". Patients are taking oral anticoagulants to treat DVT or to prevent a recurrence. Oral anticoagul
APA, Harvard, Vancouver, ISO, and other styles
2

Oh, SangHyeon, Seoyong Choi, and Jee-Eun Chung. Comparative efficacy and safety of reduced dose of DOACs in patients with atrial fibrillation. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.8.0073.

Full text
Abstract:
Review question / Objective: To compare the risk of stroke/systemic embolism (S/SE), mortality and bleeding in AF patients with reduced-dose DOACs. Rationale: Although each DOAC has its dose reduction criteria, many physicians still prefer to prescribe the reduced-dose DOACs, regardless of label adherence. However, inappropriate administration of DOACs is an important clinical problem because patients may not benefit from the recommended DOAC dose to prevent stroke and systemic embolism. Therefore, this study aims to investigate the risk of stroke/systemic embolism (S/SE) and mortality in AF p
APA, Harvard, Vancouver, ISO, and other styles
3

Bykov, Katsiaryna, Geetha Iyer, Nazleen Khan, Helen Tesfaye, Heidi Zakoul, and Sebastian Schneeweiss. Comparing the Benefits and Harms of Different Long-Term Treatments for Blood Clots – The DARE Warfarin Study. Patient-Centered Outcomes Research Institute (PCORI), 2023. http://dx.doi.org/10.25302/04.2023.noacs.151133068.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zhu, He. Postoperative bleeding of therapeutic endoscopy in patients using direct oral anticoagulant or warfarin: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review Protocols, 2020. http://dx.doi.org/10.37766/inplasy2020.4.0172.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Radić, Mislav, Hana Đogaš, Tina Bečić, Andrea Gelemanovic, Damir Fabijanić, and Josipa Radić. Non-vitamin K oral anticoagulants versus warfarin in patients with triple positive antiphospholipid syndrome – protocol for a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.10.0054.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Alomairi, Abeer, Rana Alduhaysh, Alaa Samandar, et al. Cerebral Outcomes of Warfarin Versus Non-Vitamin K Antagonist Therapy for Atrial Fibrillation: A Systematic Review and Meta- Analysis of Randomized Controlled Trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2025. https://doi.org/10.37766/inplasy2025.5.0083.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ye, Hao-Zhen, Jia-Jia Gao, He Zhou, Zhi-Wei Li, Hong-Wei Xu, and Ben Wang. The risk of postpolypectomy bleeding in patients receiving direct oral anticoagulants compared to warfarin or non-anticoagulants: a systematic review with meta-analysis of cohort studies. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.10.0124.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Halwa, Stephanie, and Lydia Harriss. Electromagnetic (electronic) warfare. Parliamentary Office of Science and Technology, 2025. https://doi.org/10.58248/pn749.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ekström, Thomas. Kunskapsöversikt: Lärdomar från Ukraina med relevans för svensk infrastruktur. Swedish Defence University, 2024. https://doi.org/10.62061/xjyn5209.

Full text
Abstract:
The Russian war in Ukraine is a humanitarian disaster for the Ukrainian people. However, the people, and indeed the whole society, has demonstrated a remarkable resilience. There is consequently much that other countries can learn by studying how Ukraine has been able to muster such resilience in the face of the Russian full-scale invasion. This report focuses on what Swedish authorities in the communications, energy and transportation sectors can learn from what academics, organisations, and nations have already published regarding resilience in critical infrastructure systems. Judging by the
APA, Harvard, Vancouver, ISO, and other styles
10

Williams, Sarah, and Simon Brawley. War and the future of war. Parliamentary Office of Science and Technology, 2025. https://doi.org/10.58248/hs93.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Warfarin' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography